0001493152-17-000089.txt : 20170104 0001493152-17-000089.hdr.sgml : 20170104 20170103193155 ACCESSION NUMBER: 0001493152-17-000089 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170103 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170104 DATE AS OF CHANGE: 20170103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marina Biotech, Inc. CENTRAL INDEX KEY: 0000737207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112658569 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13789 FILM NUMBER: 17503316 BUSINESS ADDRESS: STREET 1: 1176 TOURMALINE DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 4259083600 MAIL ADDRESS: STREET 1: 1176 TOURMALINE DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: MDRNA, Inc. DATE OF NAME CHANGE: 20080610 FORMER COMPANY: FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 3, 2017

Marina Biotech, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-13789	11-2658569
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

17870 Castleton St., Ste. 250, City of Industry, CA		91748
(Address of principal executive offices)		(Zip Code)

Phone: 626-964-5788 Fax: 626-964-5988

(Registrant’s telephone number and fax number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On January 3, 2017, Marina Biotech Inc. (the “Company”) issued a press release announcing that the Company was granted a patent for Bacteria Mediated Gene Silencing (EP 08768475.9, European Patent 2173875) claims by the European Patent Office. The granted claims relate to the Company’s tkRNAi technology being utilized in its CEQ508 program that is being developed to treat familial adenomatous polyposis (FAP).

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1: Press Release of Marina Biotech Inc. date January 3, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Marina Biotech, Inc.
	(Registrant)

Date: January 3, 2017
	/s/ Joseph W. Ramelli
	Joseph W. Ramelli
	Chief Executive Officer

EX-99.1 2 ex99-1.htm

News Release

Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing

City of Industry, Calif. (January 3, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that the European Patent Office intends to grant the company a patent for Bacteria Mediated Gene Silencing (EP 08768475.9, European Patent 2173875).

The granted claims relate to the company’s tkRNAi technology being utilized in its CEQ508 program that is being developed to treat familial adenomatous polyposis (FAP). Marina’s patent portfolio around tkRNAi and its CEQ508 program includes 14 issued patents worldwide. The claims are broad, and cover a prokaryotic vector comprising a promoter for generating siRNAs. Targets for the siRNA include beta-catenin. The vector can include an invasion factor, and a lysis regulator. An invasive bacterium including the vector is also encompassed. Marina Biotech will continue to expand its development of tkRNAi to cover other therapeutic targets as permitted by the granted patent- including Ras, APC, HER-2, MDR-I, MDR-2, FATP4, SGLUT-1, GLUT-2, GLUT-5, apobec-1, MTP, IL-6, IL-6R, IL-7, IL-12, IL-13, Ra-I, IL-18, p38/JNK MAP kinase, p65/NK-kB, CCL20, Claudin-2, Chitinase 3-like 1, apoA-IV, MHC class I and MHC class II.

“We are excited by the recent positive developments from the CEQ-508 program and looking forward to expand bacteria mediated gene silencing to other therapeutic areas protected by our patent portfolio, including oncology, diabetes, and hyperlipidemia”, stated Dr. Vuong Trieu, Chairman of the Board at Marina Biotech. “This unique ability to orally deliver oligo therapeutics across different species and kingdoms will open up applications not possible with any other delivery platforms”.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103- next generation celecoxib- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com.

Marina Biotech Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to successfully integrate its business operations with those of IthenaPharma; (ii) the ability of Marina Biotech to obtain funding to support its clinical development; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech’s most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

For Marina inquires:

Joseph Ramelli

CEO

Marina Biotech, Inc.

(626) 964-5753

GRAPHIC 3 image_001.jpg begin 644 image_001.jpg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

\DG>[2-ZBJ,3EBQQA OR_\"!SG MW&.>3_.J\UVJ$+G^+C../?CMTQUJ8QJ2T4'S*4DXIWLE*23;MO)).W2]KZ79 M7Q%/#TYU:THQC%TTFI)J3J1BU9[-+F:OK>U]+FM16:DC^:SJ 4<9#ZY]L@X_.FH3E&].#F[:I75OG;H MM=B)8JC3;5><:+;_ '*FU>M#I4AM>,EK%JZ:::=F:M%9+7D9<-$?F(.5(X/3 MZ\=?Y9YY7[6#PV"2OW,8QSGUS[YQ]2*7+46\+-+F:U+=^\]TOBMKRM&K166MY'NV<;PHPIX[<>N?T MZ=#S5?[0LS8DCP5)((&!@=./_KU<:55KF<&H[IIIMQ;]V23M=2C9NU[7MK84 M'*M"M+#NC6EAYW33@!.,8QUSZY MX/X'FHVNXA*5QER?7Z]!W]0,YZXJ5%N7(HRYDKRM&_+I=?*W72WF14KT:*A* MO5ITX56HTIJ:DJDFES136B<9-QW>U]-EJT55MY!(9,=@A/&/O;L?7IWJU1)< MKMZ?BKFS4EI))/?1W5GK%WLMXM/RO;7<8Y' /?//<8QV[CGFH70<@XVL#G'< M'H<]NY__ %YJS2-T/T/\J<9Q)E-WKEU>VEL+<1O=1-::5>:A->P?: /B?\)];\!WNC^(O#'B/QGK M/C&"#XJ^$?B+XH\+:QI=QX9EOY5MO"^EWY\ SZEJ$FL;5%M )/T^_;;\:WOP M;$_#S]H8VE]J?@_X&_$6W\1_%;3M,A:\U%?A3XJT+6OA[XNU_3K%60SWG@P M^*].\8M*'7[/IVAZB1!%(-"\9>.-0USQ!_P +4^/WASPEKW@V MY\.Z=-X>NG\4_P!B^%?%6C3ZS/<>'X=/L[F?Q9/HNI6[66G^'I!_96J$_I/^ MRM^U?HW[2MKXVT74_ OB;X1_%SX6ZWI?ASXG_"+Q;(ESK7A"]UK2)]1T36=) MU& '3]4T#7;*WN[KP_?V4,!FM[>Z:2, QBO(-8_99^*W@/7=<7X0^(?"&H^% M-=\1ZGXIT;3/&,?B32]>\!^(]5C>36]9T.]T*":+4=>NX4%KHVO36M[K'AFR M75!HFG3#6M2NK+XK_8@T7XN^/?C1^U9\6/A?J_ACX=W.N?&:+X2?$&ZNO"5S MXOT-+?\ 9YL8? 5KI_A37+O6+.76Y-4U";4[R\U#4+K5=:-Y),-4U-B+2RL? M=QU/"X^<\31J1C7G"DYS:MK&G"%FKJUE&VVK6C:>OP61YEG_ DY95F. S"O MAHU:[ITJ> ]KA:4,37J8B+IY@ZO+7YE64Y_NH>SDY4M>1M^!_P#!:WPAJ?[& M_P 3_@+_ ,%/?V=63PQ\2M'\=Z=\._B[:Z3>)9^'_B#X3OT;4+2W\71JB+=+ M,NE:KIM_\I*WNI:9O:221Y&^^/CUK]K^TKXF_8NG$^)_%GAWPU\;O GC/Q? MI.H:+J.M:9.MCK?P]T;7/#UQ=?V4YM[_ %72+Z\M]6NS?^6L.F>:(1B6=W_( M/_@OG^T5XC\9^#O@S^PU;:QX>^)'QKUSQ_I^I^,+'P7"UA:375SH-IVK7EQJ$YU1"8O,:.# 81@1_NE\//V3/&/@G3/V#K6'5;&6T_9I^&, MO@_QJVIX.JZKJLO@73='O]2MBN<&YU/1]0DES_STB/W<5C0Y,!/#U\7.,YT8 M5%JE:7.YSIRNVVDE.%U9\R6Z31EBO[1SW%YVLJIXJ%-5<%*I24Y450_V;#N= MH0U_P=X^8VWQ@^%>N'P9\0M,+^9'J$VGP M?9M*\3Z.7_?-X7\66 @UFREF"L;MM31D(C+'Y._:C\3>(?CC?_$SPOX4U;6= M+^&G[/7@WQ5KWC3Q'X;U6ZTA?%GQ*L_#6K-I?A'3KJS)*IX5 GUG6 Q<"6.P M5&._-?0WQ\^ WQ#U3QEI7Q5^ FK^'_#'Q*GT6^\$>+F\0"^.D^*/"-]O^P3W M/V('.N>#-2E77/#WG81B=1BPRR,C='H_[/*^%OV9O$OP8\-7D=WXA\3>"_$E MAK7B;59+R-O$_C[Q?I]Y:^)?$]^;DL&DUG49)+Q?*)VQL Q8!';.G6P%.O/& MJ<*D<9-6HJRSW5V=0_XE4<]SJCZA=+OO)K^V5M1F==Q1BV1M*"OCJYT+Q]^V)? M?$/XQ^&O&FO>"/#G@C[?I'[.5IINKWFG:=XFUWP[/+)<>.M>CM=&UO0-#MH-,\.>%/BOKSZC>17$ MG@W3H%M-=T;PT+;2[_.J:TMM%;+,UUI_EI&8A)*LLHB]&T_]BG]FK3[*TL[? MP%)!:VL,<) \4>,K1";>W$3SZE%I_B2*UN+XF*V:5KR"(()#Y(#>";=V[)1B!CA9*%.<(PK*O*FYOV?,XF[^S3\;K?XT^ M (-VMI;K;*;*Y;R;VS:) &2;;(\ MCAF7\Z_#^K_"&_\ CW^U);?&P?$O66L_B9;6WA6S\,CXRZU9V%BVCQ?;?]"\ M&[K6$7 33]HN R/Y#_9#MCGS]<:)^S!J'P2^-^F?$'X-W&C>&_AEXE\/'2?B MUX)U34[UX3-:2S7EIXJT6:\U"^F&I01?:Q(K% RG+NZLZP]!^SMX)M/!?Q0_ M:(\2W'BWP)KL/Q>^(FG^*?#&F^']?M+[55TNWT5;%9M5@N#MM[\_(CI!N640 MGDB-"=J>)RS#RQ&(HREB*%>*]E&ZH5*;C>,H\SC56DEI[KO'2_4Y<1AN*,VQ M?#&%S#V&78C+5BZ-?EJ*M'$X55:D,OC)?N&IT<%'#TJE5N7MJD)UN6#J.*^0 M+;4O!U_\>_A#X<_9-\2?$30/$%IXEMM1^)VD>-/$?Q-T;PY>_#V!8OM\+^&O MB-C^T-8C9F&E+H\:"W,UT-0&)K*OI?QIJFHQ_M^? [0[?4]2@TF[^"WC.\N- M*BOA!8S2?:+EEFO-+_Y>KAE*AFQ^["CKOS7=?M$?"G4?B)XS^"7C_P !ZMX7 ML/$?P8^(\7B3Q/>ZE=XG_P"$*FL);;Q!9R'36"*["&T91>1LFR*4QE L@:CJ MO@FV\5_M5_"_XO:+XV\%W>@^'/AIXG\'7NCVOB6QGUI]9U3SY(7TK3K;=+< M)/FY%S\T82W\I%+R"JJ8W!5H4ZT::A[7A[,LDE!SYY0Q.*QN(KTL>Y)?VLOVEO%'PI\9:G9>-/A0/ NM^'_">J MZVY\$^,K*\T">/7/!^O:$"'@@UF*PM5LM6&#IFH0V[9!NHP;RKS0S2,;;45 M11J5BT$F7:,[-#P%X4TWP+^T;^T-\2M;\=_#^+2/B+'X,73=*D\36ECKVEWO MA[1$TB^?6([S:MFSK]FBLH(V)N2)S(O[J(-P/[5'P(A\5WNO^*?A+X\\(?#W MX@>+O">H^%?'FE^(+VQLO"OC?P=K&F-8)J.KVUJV]KFQ:\D;3+QPWGF_NSO# M#Y]_K&!Q6-P6'J1CAZ=/ 9=06)^/FJ8/ 4,/7G*"C%I5ZM*I-I2:IR:C*4_B M,XY;GV5&WM-"BGU2YG."P,*(0& MP<+("!E17Q5-H'Q1_:JL_''[0_AOQ9K_ ('DT/4HK7]F'P[8:H;32K^#PS?F MZG\2:UI^"FIS>,1;BTTV,E19A+S "38'K?CCX->,]2_9X^!/P1E\?>!_#G@W M3]+\.Z3\7?$D'BJ\TVZUSPSHEO96A\*^%!;Z9>17%KKBH8=0DFO-/:"*"UCB MDF$TPC]*TS]DS]E4Z0TNE^%K"72M,B-G<3:;XW\92:;8Q62(KQW*:=XF%LTT M1-M(\=W#;L!*QB&#+CDCBLHPM2O.:I&*3MK35 MTKS=UVXC \19E2PV6X;!TU/+L/AJU.-;'GBI+VWL6Y?2_&'AF=P-3\->+--O;ZPUK3;ZVX-NC MW=H]Y:9R)8[ESG;#Z_J?\ &OS_ /!/[.]Y\"OCK:>*OA#<:%IGP>^( M>BP:=X]\&ZAJE]YR^([5VGTWQ)X>EO;_ %)YY)H+J[_M!':&0JUN%$R[VC^Z MWNK:(@S75K TJB1=ZJS2Q\QQSEBPW"1(QM/]T =J\?'1H+$3EAI2E1ERN'-# MD:3BFU;FEM+F2UU23V:/LN&J^<5<)/"Y_A:6$S/ S]E7]ABOKM*I&36U_9WEO;W M&G7%I=6\EG=0ZI'>-]DFTV>TN;BWN[22.62XCF)A4&)F'XE^)OV4_P!N#]A; M5]3\0_\ !/'Q!H/QD_9\N;^^U!_V+/B_KLVA?$+<7=R]]/!\&/BAJUAJ?\ M8?AY[R]U2ZC\+ZNT=I:,VG1:69T>[8?NU5>?^#_@7_LM:TZLH.TDITT[QA\- MN^NNK>NRZ7O8\W'970QR35/\ @LG^ MTAX%#:7\6?\ @EE^U1X;\66:-97*Z1'J'BK06N_-MX!>V6K:1X6;1-8L)YY8 MOL]RLJML!VDK(PKXIM/VFO\ @I5\9K[XE:1^P5_P3M\??LX?\+O\9WOCKX@_ M$3X@WFHZ,6\1:S;0Z!K?B.SE^(VF:9X6T&]>WT*.9QX16:ZO"R?:A"UIIH?^ MN63M^/\ 2HOXT^I_I7HT\RI4H6IX11J=9NLVF[W7N\FEO)]#YK$$YCF"C0S M'B?,:V"@WRX;#4UA)*+O[OME5J2;MHY--]K:6_ 3_@G)_P $95_9Z^(LG[3_ M .U+XYM?C9^U'*G*=:\E)).-[*R26]O)?YGT&4Y)@\BP=3!Y6ZT%5DI5*^*JO%XBJ M[MOVE62A*>[C&^D(FX27+R24&L12K2:BO?IPI MQA*CI:W/).7-KRWMRNUWG*T3,HQXW M\=? ]]\2OA'\2_AWI-S;6&K>//AQX\\':7J5\IDTVPU#Q3X:OO#MO<7L(9S* MD;:HS8%C?J%60-$ =DWXQ? +_@EY\7?AIX\_9-UWQ$_P=TO3OV='MSK^O:/J M][K6N>.%TSX:^(O EI8Z3I%C\-?A8WAG4[C4M5T[5(=5?QUJ@C_LTD6DP1DG M_H!JO/\ P?\ O\ V6J4U9*45+?;1?)6[=V^YQ8G*\+B<5A\74]K[:@I)M5& MO:7VOMRM+39W2/S$\0_L;>,]3\%?\%(?",?BW0=-F_;4G\577@G44L]1C/@I M=:^!_A[X5S+XE(TNX2YE@OM,O=9NM1@AU$WT&JN3/,;517ALG["OQ2\12_LU MVD_P<_9$^$R? GXN?!WXFZWXY^%\^M77Q!\0:=\+I_[1O/"Z6_\ PK#PO'O\ M1S7-M/>M+XD:)S8 C!OC#H7Q \/:IX"TJ\U+QIXL^),W@6]T+Q5/:#PY<6 MFKWVB?\ ",ZE$E[KFHWK:>+[=IRPR7-[O\&^.O[ WQ!\:?M<:K^T3X9\,_!? MQKX6N_A?\*?!.F> _B%J[:#96@^'.J^);^6VU2QB^"/Q#TZZT;6(]9MXQ::= MJWA86 TH))_:*7%NNE?LM/\ P?\ O\ V6HX^_X?UJ95&ZF&G;3#J:4;OW^> M'[CRX_#),VIZ7]J\*'S!YJPPQ".0.FC_ +('Q N?@!^V-\,[CP?^SS\) M-<_:1TG6M/T/2/@II.KVOAC2UO/ACI_P^BE\3:EJ>E:-#J-VQTS^TT:/P];B MV.I3&=9S,-OZF1]_P_K4<_\ !_P+_P!EJI5YVA&G&E"$)2DDX<[]^;G+5M;R MDVG9M)VV1']EX>=/V=65:3]Y.=.I*E4<6VHQ&M1TN^A\*V^C^ M%M!F06UQ?1#11J%SJ@5#((I+1O/^U?JN5F0E55V;S)G?RH5E"M+/),JR,.DH MBDC+CH